Results 131 to 140 of about 742,291 (286)
International Journal of Cancer, EarlyView.ABSTRACT Evidence to guide the treatment for patients with metastatic castration‐resistant prostate cancer (mCRPC) and Homologous Recombination Repair (HRR) gene alterations outside of clinical trials remains limited. This was an observational, cohort study, including mCRPC patients with tumor harboring HRR alterations, progressed on a prior androgen ...
Lorena Incorvaia +35 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT Early diagnosis remains challenging, recurrence rates remain high, and platinum resistance frequently develops in ovarian cancer (OC), collectively representing major barriers to long‐term patient survival. DNA methylation (DNAm), as a relatively stable yet dynamically modifiable epigenetic signature, can capture alterations in tumor states ...
Min Xing +6 more
wiley +1 more source
Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer
International Journal of Cancer, EarlyView.ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue +6 more
wiley +1 more source
International Journal of Gynecology &Obstetrics, EarlyView.Abstract Lynch syndrome and BRCA‐mutation associated malignancies are fortunately rare. Affected patients have an increased risk of cancer diagnosis at a young age, often significantly overlapping with their reproductive years. In helping these patients, oncologists must navigate the following areas of care: cancer prevention, impact of cancer ...
Anna Weimer +20 more
wiley +1 more source
iNew Medicine, EarlyView.ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid +4 more
wiley +1 more source
ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential
iNew Medicine, EarlyView.ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang +5 more
wiley +1 more source
PARP inhibitors for cancer treatment
, 2011 Poly(ADP-ribose) polymerase (PARP) inhibitors are a promising, novel class of anticancer agents to be used either alone or in combination with chemotherapy and radiotherapy.
GRAZIANI, GRAZIA
core
Journal of Applied Toxicology, EarlyView.ABSTRACT A Cu(II) complex derived from a pyrimidine with the isatin group was synthesized and tested for its cytotoxic effects on A549 lung cancer and MCF‐7 breast cancer cell lines, as well as its effects on apoptosis‐associated cell death and cell cycle regulation in A549 cells. To evaluate cytotoxicity, MTT assays were performed at 24, 48, and 72 h,
Müjgan Kesik Oktay +4 more
wiley +1 more source
Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives
JSFA reports, EarlyView.Abstract Cancer is constantly rising mortality rates due to its late prognosis, poor management, and expensive treatment. Multi‐sectoral approaches for cancer management include hygienic practices, synthetic drug exploitation, radiation therapy, and diet modifications.
Muhammad Maaz +10 more
wiley +1 more source
Sensitizing Colorectal Cancer to PARP Inhibitors: Biomarkers, Mechanisms, and Combination Strategies. [PDF]
Int J Mol SciElesnawy M, Masood E, Naik A.
europepmc +1 more source